TrialAnnals of hematology2018

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

David Cella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.